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Background
Since several years dynorphin, a member of the opioid
peptide family, was suggested to play a regulatory role in
numerous functional pathways of the brain, including
anxiogenic effects in male mice [1]. However, emotional
control and stress response depend on the hormonal state
and differ between sexes, therefore we now investigated
female prodynorphin-deficient (Dyn KO) mice.
Methods
Dyn KO mice were generated by replacement of the entire
coding region of the prodynorphin gene [2] and back-
crossed onto C57bl/6N. Age and testing experience-
matched female intact and ovariectomized (OVX) Dyn
KO and wildtype (WT) mice at 3-8 months age were tested
in all experiments. Anxiety (open field test, OF; elevated
plus maze test, EPM; light dark test, LDT) and stress-
related behaviour (forced swim test, FST; tail suspension
test, TST) was investigated in correlation to the estrous
cycle in intact female WT and Dyn KO mice and in OVX
WT and Dyn KO mice treated with the general estrogen
receptor (ER) agonist 17β-estradiol (E2), and specific ago-
nists for ERα (PPT), ERβ (DPN) or GPER (G1) two hours
before testing.
Results
In the EPM, Dyn KO mice showed a significant anxiolytic
phenotype with about double time spent, distance trav-
elled and entries in the open arm at all estrous stages com-
pared to WT mice, while differences in the OF and LDT
were less prominent than in male mice. Strikingly, the
drop in ambulation observed in the OF, LDT and EPM
during the proestrus phase in WT was absent in Dyn KO
animals. In addition, the influence of the estrous stage on
the behaviour in stress tests was abolished by the pro-
dynorphin deficiency. Significant differences between
OVX WT and Dyn KO mice were observed after DPN and
G1 treatment, which both elicited anxiogenic effects in
WT, but not in Dyn KO mice. In contrast, no differences
were observed regarding the anxiolytic effects of PPT.
Conclusion
Our data suggest that the anxiogenic effects mediated by
activation of ERβ and/or GPER may depend on the activa-
tion of κ opioid receptors. Pharmacological experiments
aiming to solve this question are presently conducted.
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